We are live on ! Find out more

Quoin Pharmaceuticals

QNRX

Market cap $18.1M

3.76 USD

-0.15

3.84%

At close Updated Nov 10, 11:56 AM EST

1 day

-3.84%

5 days

-4.33%

1 month

-13.76%

3 months

-29.85%

6 months

-40.13%

Year to date

-73.3%

1 year

-53.81%

5 years

-99.99%

10 years

-100%

About: Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Employees: 6

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.1%

Neutral 92.9%

Negative 0%

Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome

Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW episode. ASHBURN, Va.

Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome

Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results

– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces Private Placement Financing of Up to $50.0 Million with Healthcare-Focused Institutional Investors – FDA Clears First-Ever IND for Peeling Skin Syndrome (PSS), Grants Rare Pediatric Disease and Fast Track Designations to QRX003 for PSS; EMA Grants Orphan Drug Designation to QRX003 for PSS Subsequent to Quarter End – Advances QRX009 Topical Rapamycin Platform Toward Clinical Testing in a Number of Indications – Expands NETHERTON NOW Awareness Campaign with New Video Featuring a Pediatric Critical Care Physician and Her Daughter –Peer-Reviewed Paper on QRX003 for Netherton Syndrome Published in Dermatology and Therapy Subsequent to Quarter End ASHBURN, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026

ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient's Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with QRX003, Patient's Skin Remains Fully Clear and Pruritus Free – No Adverse Events have Been Reported for the Patient – Full Recruitment in Ongoing Phase 2/3 Netherton Syndrome Study Expected to Complete by End of 2026, with Topline Data Expected in Q2 2027 ASHBURN, Va., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union – Designation Represents Eighth Important Regulatory Milestone for QRX003 – QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration – In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe and Japan as well as Pediatric Rare Disease and Fast Track Designations in the US ASHBURN, Va., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome – Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe – Peeling Skin Syndrome Currently Has No Approved Treatment ASHBURN, Va., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

See News Rankings

Price charts implemented using Lightweight Charts™